



25

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: David Calderwood, *et al.*

Serial No.: 09/399,083

Filed: September 17, 1999

For: 4-Aminopyrrolopyrimidines as Kinase Inhibitors

Attorney Docket No.: BBI-6043CCPCPA
(formerly BBI-6043CCP)

Group Art Unit: 1624

Examiner: D. Rao

RECEIVED
FEB 05 2002
TECH CENTER 1600/2900Commissioner for Patents
Washington, D.C. 20231NOTIFICATION OF CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir:

The Attorney Docket Number of the above-identified patent application has changed.
Please take notice that the correct docket number for this application should now be as follows:

"BBI-6043CCPCPA" instead of "BBI-6043CCP"

Please reference BBI-6043CCPCPA on all future correspondence and continue to direct
all correspondence to the principal attorney of record, Giulio A. DeConti, Jr.

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the
United States Postal Service as first class mail in an envelope
addressed to: Commissioner for Patents, Washington, D.C.
20231 on:

January 2, 2002
Date
Peter C. Lauro
Peter C. Lauro, Esq. Registration No. 32,360

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Peter C. Lauro
Peter C. Lauro, Esq.
Registration No. 32,360
Attorney for Applicants